Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

Novartis to Invest USD 500 Million in New Singapore Facility

By BiotechDaily International staff writers
Posted on 19 Nov 2012
Novartis (Basel, Switzerland) will pay more than USD 500 million to construct a new biotech production site in Singapore to support its growing pipeline of biologics.

First announced in 2007 as a USD 700 million investment, the facility was put on hold after Novartis formed a biologics production partnership with Lonza (Basel, Switzerland), a global biopharmaceuticals supplier, in 2008. The project has now been revived, and construction of the new site is planned for early 2013, and is expected to be operational by the end of 2016. The reasons behind the delay and the decision to reduce the investment by USD 200 million were stated as a desire to better align capacity needs and scope requirements with the future pipeline.

The new facility will focus on drug substance manufacturing based on cell culture technology, such as monoclonal antibodies treatments for cancers and autoimmune and respiratory diseases. The new facility will be based at the same location as Novartis’ existing pharmaceutical production facility in Tuas (Singapore), and will be designed to operate in a flexible manner to handle both small and large-scale volumes and to support clinical and commercial production of potential new products.

“We have chosen Singapore as strategic supply point as it offers a wide range of advantages due to its strong local biomedical presence and knowledge, skilled labor, as well as proximity to growth markets in Asia,” said Joseph Jimenez, CEO of Novartis. “This investment further strengthens our strategy to establish key strategic sites based on technological competencies. Singapore will be strengthened through a new state-of-the-art facility for biotechnology which is a growing segment of our business.”

Novartis already has several operations in Singapore, including its tropical diseases institute, the Asia-Pacific head offices, and two production facilities for its eye-care unit Alcon.

Related Links:

Novartis
Lonza




comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This micrograph depicts the presence of aerobic Gram-negative Neisseria meningitidis diplococcal bacteria; magnification 1150x (Photo courtesy of the CDC - US Centers for Disease Control and Prevention).

Infection by Meningitis Bacteria Depends on Dimerization State of Certain Host Cell Proteins

A team of molecular microbiologists has untangled the complex three-way interaction between the non-integrin laminin receptor (LAMR1), galectin-3 (Gal-2), and the pathogenic bacterium Neisseria meningitidis.... Read more

Drug Discovery

view channel

Molecule in Green Tea Used as Carrier for Anticancer Proteins

A molecule that is a key ingredient in green tea can be employed as a carrier for anticancer proteins, forming a stable and effective therapeutic nanocomplex. This new discovery could help to construct better drug-delivery systems. Some cancer treatments depend on medication comprising the therapeutic drug and a carrier... Read more

Lab Technologies

view channel
Image: Yale West Campus is organized into research institutes and core facilities — all designed to promote collaboration and interdisciplinary dialogue (Photo courtesy of Yale University).

American and European Partners Establish a Microscopy Center of Excellence

A prominent American university has announced a partnership agreement with a major European producer of microscopes and imaging tools that will establish a center for the use of cutting-edge imaging technologies... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.